These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Topilsky Y; Hasin T; Raichlin E; Boilson BA; Schirger JA; Pereira NL; Edwards BS; Clavell AL; Rodeheffer RJ; Frantz RP; Maltais S; Park SJ; Daly RC; Lerman A; Kushwaha SS Circulation; 2012 Feb; 125(5):708-20. PubMed ID: 22207715 [TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256 [TBL] [Abstract][Full Text] [Related]
4. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Keogh A; Richardson M; Ruygrok P; Spratt P; Galbraith A; O'Driscoll G; Macdonald P; Esmore D; Muller D; Faddy S Circulation; 2004 Oct; 110(17):2694-700. PubMed ID: 15262845 [TBL] [Abstract][Full Text] [Related]
5. Rapidly progressive cardiac allograft vasculopathy in early onset regressed with everolimus treatment in an adult cardiac recipient. Ishida J; Kinugawa K; Shiga T; Imamura T; Hatano M; Maki H; Inaba T; Yao A; Hirata Y; Nishimura T; Kyo S; Ono M; Nagai R Int Heart J; 2012; 53(6):388-90. PubMed ID: 23258141 [TBL] [Abstract][Full Text] [Related]
6. TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? Mehra MR; Uber PA J Heart Lung Transplant; 2003 May; 22(5):501-4. PubMed ID: 12742410 [No Abstract] [Full Text] [Related]
7. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. Lamich R; Ballester M; Martí V; Brossa V; Aymat R; Carrió I; Bernà L; Campreciós M; Puig M; Estorch M; Flotats A; Bordes R; Garcia J; Augè ; Padró JM; Caralps JM; Narula J J Am Coll Cardiol; 1998 Aug; 32(2):413-9. PubMed ID: 9708469 [TBL] [Abstract][Full Text] [Related]
8. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients. Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928 [TBL] [Abstract][Full Text] [Related]
9. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation. Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086 [TBL] [Abstract][Full Text] [Related]
10. Comparative Study of Pediatric Coronary Allograft Vasculopathy Between Single Centers in North America and United Kingdom. Fenton M; Mahmood A; Burch M; Simmonds J; Kuhn MA Transplant Proc; 2018 Dec; 50(10):3705-3709. PubMed ID: 30577259 [TBL] [Abstract][Full Text] [Related]
12. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P; N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570 [TBL] [Abstract][Full Text] [Related]
13. Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant. Shuker N; Bouamar R; Hesselink DA; van Gelder T; Caliskan K; Manintveld OC; Balk AH; Constantinescu AA Exp Clin Transplant; 2018 Jun; 16(3):326-332. PubMed ID: 28969528 [TBL] [Abstract][Full Text] [Related]
15. Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant? Doggrell SA Expert Opin Investig Drugs; 2004 Feb; 13(2):161-3. PubMed ID: 14996650 [TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. Valantine H J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321 [TBL] [Abstract][Full Text] [Related]
17. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation. Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P; Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361 [TBL] [Abstract][Full Text] [Related]
18. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression. McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506 [TBL] [Abstract][Full Text] [Related]
19. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds? Edelman ER; Danenberg HD Circulation; 2003 Jul; 108(1):6-8. PubMed ID: 12847052 [No Abstract] [Full Text] [Related]